SC
DMK

Sophrosyne Capital’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Sophrosyne Capital’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-600
Closed -$267K – 90
2013
Q4 		$267K Buy
+600
New +$263K 0.23% 46

Other funds holding DMK

AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
GP
Grow Partners San Diego, California $4.81M AUM 7.86% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
SM
Scoggin Management New York $1.04B AUM 232.32% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sophrosyne Capital's DMK Position: Q1 2014 in Review

Sophrosyne Capital sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2014, closing a stake of 600 shares — an estimated $267K sold.

Sophrosyne Capital first reported a position in DMK in Q4 2013 and held it in 1 quarter. The position peaked at $267K in Q4 2013. 20 funds tracked by Wall St. Rank hold DMK as of Q1 2014.

  • Sophrosyne Capital reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 600 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2014, an estimated $267K.
  • Sophrosyne Capital first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q4 2013 and held it in 1 quarter.
  • Sophrosyne Capital's DMK Pharmaceuticals Corporation Common Stock position peaked at $267K in Q4 2013.
  • 20 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2014.

Based on Sophrosyne Capital's 13F filing for Q1 2014, filed 14 May 2014.